WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Iran helicopter crash: President Raisi, the supreme leader's protege, dies at 63
Weddings should be subsidised by the government for low
Indiana professors sue after GOP lawmakers pass law regulating faculty tenure
IF starring Ryan Reynolds lands at the top of a lackluster box office with less
Judge: Alabama groups can sue over threat of prosecution for helping with abortion travel
Star guard Kadary Richmond transfers to St. John's from Big East rival Seton Hall
Shanghai rout Zhejiang as unbeaten run reaches 10
Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
Why the verdict in New Hampshire's trial over youth center abuse is being disputed
Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
Weddings should be subsidised by the government for low